Scarpelli, Daphne B.Turina, Claire B.Kelly, Patrick D.Khudanyan, ArpineJaboin, Jerry J.McClelland, Shearwood, III.2022-08-172022-08-172020-03Scarpelli DB, Turina CB, Kelly PD, Khudanyan A, Jaboin JJ, McClelland S 3rd. National trends in management of adult myxopapillary ependymomas. J Clin Neurosci. 2020;73:162-167. doi:10.1016/j.jocn.2019.12.049https://hdl.handle.net/1805/29805Myxopapillary ependymomas (MPE) are WHO Grade I ependymomas that annually occur in 0.05–0.08 per 100,000 people. Surgical resection is the recommended first line therapy. Due to the rarity of the disease, there is a relatively poor understanding of the use of radiotherapy (RT) in managing this disease. The National Cancer Database (NCDB) was analyzed for patterns of care for adult MPE diagnosed between 2002 and 2016. Of 753 qualifying cases, the majority of patients underwent resection (n = 617, 81.9%). A relatively small portion received RT (n = 103, 13.3%) with most receiving RT post-operatively (n = 98, 95.1%). The likelihood of patients to undergo resection and RT was associated with patient age at diagnosis (p = 0.002), tumor size (p < 0.001), and race (p = 0.017). Chemotherapy was not widely utilized (0.27% of patients). One limitation of our analysis is that there was no data on progression free survival (PFS), an important outcome given the high survival rate in this disease. Surgery remains the primary means to manage adult MPE. For spinal MPE, it is understood that gross total resection (GTR) should be attempted whenever possible as GTR has been associated with improved PFS in several studies. The impact of RT on overall survival (OS) is indeterminate given the 1.6% death rate in the cohort. Analyses of the impact of RT on PFS in a larger database would be beneficial for determining an algorithm for post-operative and definitive RT in this disease entity.en-USPublisher PolicyMyxopapillary ependymomasRadiotherapyNCDBSpineArticle